|
|
|
|
Collaborating with a single CDMO offers numerous advantages, including accelerated speed to market and avoidance of costly tech transfers. For biopharma companies navigating the drug development journey, finding a partner with end-to-end capabilities in the U.S. can be a challenge.
|
|
|
|
|
Optimizing plasmid DNA, expression systems, and early development assessments accelerates timelines by improving protein yields, reducing risk, and enabling faster, high-quality transitions to clinical stages.
|
|
|
|
|
Accelerate your biologic journey from discovery to clinical batches with a CDMO that offers programs tailored for a seamless transition between discovery, drug substance, and drug product — all within the U.S.
|
|
|
|
|
Getting a promising drug candidate from formulation development to clinical phase production and commercial manufacturing can be daunting. Proper formulation development has a huge impact on whether a tech transfer to clinical phase fill/finish is successful.
|
|
|
|
|
|
Scaling Product From Bench To Market
|
Offering comprehensive development and manufacturing services in the U.S. for the entire lifecycle of your sterile drug product. Leverage in-depth expertise and capabilities, from early clinical through large-scale commercial.
|
|
• Request Information
|
|
|
|
|
|
|
|
